The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.

Inclusion Criteria:

• Planned cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens;
• History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye;
• Best corrected visual acuity (BCVA) of 73 letters or worse in the study eye with expectation of improvement after surgery;
• Understand and sign an informed consent document;
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Pre-existing macular edema in the study eye;
• History in the study eye of retinal detachment, wet age-related macular degeneration, chronic or recurrent inflammatory eye disease, or prior procedures;
• Planned cataract surgery in the fellow eye after randomization and prior to the Day 90 postoperative study visit or through study exit;
• Planned multiple procedures for the study eye during the cataract/intraocular lens implantation surgery;
• Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, as specified in protocol.
• Participation in any other clinical study within 30 days of the screening visit;
• Females of childbearing potential who are breast feeding, have a positive urine pregnancy test at screening, are not willing to undergo a urine pregnancy test upon entering or exiting the study, intend to become pregnant during the study, or do not agree to use adequate birth control methods for the duration of the study;
• Other protocol-defined exclusion criteria may apply.

Full analysis set, defined as including all randomized participants who completed implant surgery and had at least one on-therapy postsurgical visit.

Reporting of adverse events (AEs) began once informed consent was obtained from the subject and continued through Day 90 (or Day 120, if unresolved macular edema present at Day 90). Ocular AEs are presented for both study eye and non-study eye combined.

An AE was defined as any untoward medical occurrence in a subject after signing the informed consent document. AEs were reported as pretreatment, treatment-emergent, and posttreatment. Reports of AEs were obtained through solicited and spontaneous comments from the participants.